These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Boceprevir for HCV in patients with HIV: where next? Osinusi A; Naggie S Lancet Infect Dis; 2013 Jul; 13(7):563-4. PubMed ID: 23768748 [No Abstract] [Full Text] [Related]
6. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients. Macías J; Rivero A; Cifuentes C; Camacho A; Neukam K; Rivero-Juárez A; Mira JA; Torre-Cisneros J; Gómez-Mateos J; Pineda JA Enferm Infecc Microbiol Clin; 2013; 31(7):424-9. PubMed ID: 23453582 [TBL] [Abstract][Full Text] [Related]
7. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. Lok AS; Gardiner DF; Hézode C; Lawitz EJ; Bourlière M; Everson GT; Marcellin P; Rodriguez-Torres M; Pol S; Serfaty L; Eley T; Huang SP; Li J; Wind-Rotolo M; Yu F; McPhee F; Grasela DM; Pasquinelli C J Hepatol; 2014 Mar; 60(3):490-9. PubMed ID: 24444658 [TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C. Kanda T; Yokosuka O JNMA J Nepal Med Assoc; 2011; 51(181):41-8. PubMed ID: 22335095 [TBL] [Abstract][Full Text] [Related]
9. [HCV reinfection after liver transplantation - management and first experiences with telaprevir-based triple therapy]. Herzer K; Papadopoulos-Köhn A; Timm J; Paul A; Jochum C; Gerken G Dtsch Med Wochenschr; 2013 Sep; 138(36):1759-64. PubMed ID: 24002874 [TBL] [Abstract][Full Text] [Related]
10. [Current indications for triple therapy in hepatitis C virus infection]. Molina Pérez E; Fernández Castroagudín J; Domínguez Muñoz E Gastroenterol Hepatol; 2012 Apr; 35(4):266-77. PubMed ID: 22410706 [TBL] [Abstract][Full Text] [Related]
11. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase? Pascale A; Serfaty L J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419 [TBL] [Abstract][Full Text] [Related]
12. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. Vierling JM; Davis M; Flamm S; Gordon SC; Lawitz E; Yoshida EM; Galati J; Luketic V; McCone J; Jacobson I; Marcellin P; Muir AJ; Poordad F; Pedicone LD; Albrecht J; Brass C; Howe AY; Colvard LY; Helmond FA; Deng W; Treitel M; Wahl J; Bronowicki JP J Hepatol; 2014 Apr; 60(4):748-56. PubMed ID: 24362076 [TBL] [Abstract][Full Text] [Related]
13. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Flamm SL; Lawitz E; Jacobson I; Bourlière M; Hezode C; Vierling JM; Bacon BR; Niederau C; Sherman M; Goteti V; Sings HL; Barnard RO; Howe JA; Pedicone LD; Burroughs MH; Brass CA; Albrecht JK; Poordad F Clin Gastroenterol Hepatol; 2013 Jan; 11(1):81-87.e4; quiz e5. PubMed ID: 23064222 [TBL] [Abstract][Full Text] [Related]
14. Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study. Mandorfer M; Steiner S; Schwabl P; Payer BA; Aichelburg MC; Lang G; Grabmeier-Pfistershammer K; Trauner M; Peck-Radosavljevic M; Reiberger T J Infect Dis; 2015 Mar; 211(5):729-35. PubMed ID: 25214517 [TBL] [Abstract][Full Text] [Related]
15. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Rustgi VK; Lee WM; Lawitz E; Gordon SC; Afdhal N; Poordad F; Bonkovsky HL; Bengtsson L; Chandorkar G; Harding M; McNair L; Aalyson M; Alam J; Kauffman R; Gharakhanian S; McHutchison JG; Hepatology; 2009 Dec; 50(6):1719-26. PubMed ID: 19852040 [TBL] [Abstract][Full Text] [Related]
16. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593 [TBL] [Abstract][Full Text] [Related]
17. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women. Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817 [TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Ross AS; Bhan AK; Pascual M; Thiim M; Benedict Cosimi A; Chung RT Clin Transplant; 2004 Apr; 18(2):166-73. PubMed ID: 15016131 [TBL] [Abstract][Full Text] [Related]
19. Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin. Larrey D; Carenco C; Guyader D; Boyer N; Benhamou Y; Pageaux GP; Rouzier R; Marcellin P Antivir Ther; 2012; 17(5):927-32. PubMed ID: 22611092 [TBL] [Abstract][Full Text] [Related]
20. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection. Suzuki F; Toyota J; Ikeda K; Chayama K; Mochida S; Hayashi N; Ishikawa H; Miyagoshi H; Hu W; McPhee F; Hughes EA; Kumada H Antivir Ther; 2014; 19(5):491-9. PubMed ID: 24451122 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]